Top Stocks To Buy This Week

The equities market declined last week following the release of the Federal Reserve’s March meeting minutes. Amongst other indications, Fed officials are planning for several more interest rate hikes this year in addition to their investment sell-off program. Together, these activities should help taper off the record-high inflation plaguing consumers’ wallets and slow down the economy.

While the report spooked some investors—hence last week’s sell-off—some securities still performed surprisingly well. (Or at least, didn’t fall as much as their competitors.) Fortunately, our deep learning AI algorithms are here to weed them out. We’ve crunched the data to bring you the best and boldest Top Stocks from last week’s winners and losers.

New Fortress Energy, Inc. (NFE)

New Fortress Energy, Inc. (NFE) closed down 0.5% Friday to $41.65 per share, boasting over 1.28 million trades. The stock still sits up a whopping 72.5% for the year. Our AI rates New Fortress Energy A in Growth, C in Low Volatility Momentum, and D in Technicals.

New Fortress Energy is a global energy infrastructure company specializing in developing, financing, and operating natural gas facilities. This Top Stock piqued investors’ interest after Golar LNG, another natural gas company specializing in marine infrastructure, sold a $250 million stake in the company. New Fortress Energy’s shares have soared over 90% since Russia invaded Ukraine.

New Fortress Energy’s revenue soared nearly 600% from $189 million to $1.32 billion in the last three years. Meanwhile, operating income jumped from $182 million to $283.6 million, though per-share earnings have dropped from $1.62 to $0.47. The company’s return on equity sits at 7.8% compared to 61% three years ago.

Currently, New Fortress Energy trades at 21.7x forward earnings.

Tellurian
TELL
, Inc. (TELL)

Tellurian, Inc. (TELL) closed up almost 2% Friday to $5.75, adding to the stock’s nearly 87% gains YTD. The company’s shares traded almost 16.55 million times throughout the trading session. Our AI rates the company B in Technicals, D in Growth, and F in Low Volatility Momentum and Quality Value.

Tellurian, Inc. is another U.S.-based natural gas producer hoping to profit off the Russia-Ukraine conflict. Two weeks ago, Tellurian announced they’d issued a notice to begin phase one of construction on a new Louisiana export complex. However, the company has yet to line up the $12 billion in financing needed to complete the development. Tellurian’s CEO reported that the move is necessary as “energy security” is a “leading concern” on the world stage, and the U.S. must do its part to supply natural gas to the global market as quickly as possible.

Over the last three fiscal years, Tellurian’s revenue grew 147% from $28.8 million to $71.3 million. However, the company’s operating income has taken on comparative losses, dropping from $145.9 million to $112.7 million. Per-share earnings have also dropped in the period from $0.69 to $0.28, while return on equity slipped from 65.4% to 43.5%.

Alibaba Group Holding Limited (BABA)

Alibaba Group Holding Limited (BABA) slipped 0.7% during Friday’s session, closing the day at $103.53 per share. The stock traded 20.8 million times during the day before ending down 12.85% for the year. Our AI rates Alibaba A in Quality Value, C in Growth, and D in Technicals and Low Volatility Momentum.

Alibaba is a Chinese multinational tech company that’s renowned as the e-commerce powerhouse of China. The company dipped with the broader markets last week after the SEC reported its list of Chinese-based companies at risk of U.S. delisting over disclosure concerns. While Alibaba isn’t among them, investors sold off Chinese stocks en masse after being spooked by the possibility that Chinese companies aren’t sufficiently transparent with U.S. shareholders.

In the last three fiscal years, Alibaba’s revenue soared 121.9% from $376.8 billion to $717.3 billion. Operating income has seen smaller gains, but gains nonetheless, from $61.6 billion to $109.6 billion, while per-share earnings have leapt from $33.37 to $54.68. Return on equity shrunk slightly from 15.4% to 14.7%.

We expect Alibaba to see revenue growth around 9.2% in the next 12 months. The company trades at 12.9x forward earnings.

Snap
SNAP
, Inc. (SNAP)

Snap, Inc. (SNAP) slipped 1.6% Friday, closing down 24% for the year at $35.67 per share. The stock saw over 21.7 million shares change hands on the day, with its final price falling nearly in line with its 22-day price average. Our AI rates Snap, Inc. D in Technicals, Growth, Low Volatility Momentum and Quality Value.

Snap, Inc. makes our Top Stocks list this week because… well, it’s Snap. The company owns famed social media and image-sharing app Snapchat, which is currently in a fierce competition with TikTok to retain its dominance in the market. Recent reports indicate that the company’s $5 billion in 2022 advertising revenue may be more than doubled by rival TikTok’s, which may exceed $11 billion for the year.

Over the last three fiscal years, Snap’s revenue has grown by 140% from $1.72 billion to $4.1 billion. That said, the social media site’s operating income dropped from $1.1 billion to $702 million, while per-share earnings have over halved from $0.75 to $0.31. Meanwhile, return on equity has plunged to a third of its value three years ago at just 16%.

Currently, Snap trades at nearly 68x forward earnings.

Seagen, Inc. (SGEN)

Seagen, Inc. (SGEN) dropped 2.7% Friday to $151.84 per share, slipping down 1.8% for the year. The company saw nearly 3 million trades on the day as shares remained nearly $9 over its 22-day price average. Our AI rates Seagen, Inc. C in Low Volatility Momentum, D in Growth, and F in Technicals and Quality Value.

Seagen is a biotechnology company focused on developing antibody-based cancer therapies and treatments. Though the company’s current profits are nonexistent, its business model involves heavily reinvesting in its own research and development. (For instance, last year, $1.2 billion of Seagen’s $1.6 billion revenue went toward R&D.) But those investments may begin to pay off soon, as the company’s latest cervical cancer drug to be approved by the FDA may prove to be its blockbuster breakthrough.

In the last three fiscal years, Seagen’s revenue grew from $916.7 million to $1.57 billion, for growth of 71.7%. Operating income saw even greater growth of 209.3%, rising from $220.5 million to $682 million. Meanwhile, per-share earnings soared nearly 286% from just $0.96 to $3.70 in the most recent fiscal year, while ROE has over doubled to 20.6%.

Download Q.ai for iOS today for more great Q.ai content and access to over a dozen AI-powered investment strategies. Start with just $100. No fees or commissions.